A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. However, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking. Moreover, it remains unknown whether vaccination can augment such responses. We found that a dendritic cell vaccine led to an increase in naturally occurring neoantigen-specific immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma. The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in terms of both TCR-β usage and clonal composition. Our results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vaccines have been used as an approach to enhance anti-tumor immune responses and have demonstrated encouraging results in preclinical and clinical studies, leading to an expansion of the intratumoral T cell infiltration and anti-tumor immune responses (Carreno et al., 2015; Ott et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Carreno et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1196 · Cited by 1,214
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,074
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cited by
Items 401–500 of 1,003
Present status and future perspective of peptide‐based vaccine therapy for urological cancer
Obara, W., Kanehira, M., Katagiri, T., Kato, R., Kato, Y., & Takata, R. (2018) · Cancer Science · doi:10.1111/cas.13506 · Cited by 59
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Zhang, Y., He, X., Zhang, Y., Zhao, Y., Lu, S., Peng, Y., Lu, L., Hu, X., & Zhan, M. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.130171 · Cited by 59
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level
Grenier, J. M., Yeung, S. T., & Khanna, K. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00610 · Cited by 58
Engineering neoantigen vaccines to improve cancer personalized immunotherapy
Liu, Z., Lv, J., Dang, Q., Liu, L., Weng, S., Wang, L., Zhou, Z., Kong, Y., Li, H., Han, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76281 · Cited by 58
Next-generation cancer vaccines and emerging immunotherapy combinations
Brandenburg, A., Heine, A., & Brossart, P. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.003 · Cited by 58
Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets
Servín-Blanco, R., Zamora-Alvarado, R., Gevorkian, G., & Manoutcharian, K. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1191718 · Cited by 58
Personalized cancer vaccines: adjuvants are important, too
Gouttefangeas, C., & Rammensee, H. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2158-4 · Cited by 58
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy
Sidhom, J.-W., Oliveira, G., Ross-MacDonald, P., Wind-Rotolo, M., Wu, C. J., Pardoll, D. M., & Baras, A. S. (2022) · Science Advances · doi:10.1126/sciadv.abq5089 · Cited by 57
Toward in silico Identification of Tumor Neoantigens in Immunotherapy
Zhou, C., Zhu, C., & Liu, Q. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.08.001 · Cited by 57
Strategies to overcome DC dysregulation in the tumor microenvironment
Mestrallet, G., Sone, K., & Bhardwaj, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980709 · Cited by 57
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era
Martin, S. D., Coukos, G., Holt, R. A., & Nelson, B. H. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv382 · Cited by 57
Gulbahce, N., Magbanua, M. J. M., Chin, R. G., Agarwal, M. R., Luo, X., Liu, J., Hayden, D. M., Mao, Q., Ciotlos, S., Li, Z., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0688 · Cited by 57
Neoantigen Vaccines Pass the Immunogenicity Test
Linette, G. P., & Carreno, B. M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.007 · Cited by 57
Self-citationTumor-Specific T Cell Activation in Malignant Brain Tumors
Mohme, M., & Neidert, M. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00205 · Cited by 58
T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
Janelle, V., Rulleau, C., Testa, S. D., Carli, C., & Delisle, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00276 · Cited by 58
Mass Spectrometry-Based Identification of MHC-Associated Peptides
Kote, S., Piróg, A., Bedran, G., Alfaro, J. A., & Đapić, I. (2020) · Cancers · doi:10.3390/cancers12030535 · Cited by 57
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
Salvatori, E., Lione, L., Compagnone, M., Pinto, E., Conforti, A., Ciliberto, G., Aurisicchio, L., & Palombo, F. (2022) · npj Vaccines · doi:10.1038/s41541-022-00433-9 · Cited by 57
Neo approaches to cancer vaccines
Delamarre, L., Mellman, I., & Yadav, M. (2015) · Science · doi:10.1126/science.aab3465 · Cited by 57
Tiffen, J. C., Wilson, S. P., Gallagher, S. J., Hersey, P., & Filipp, F. V. (2016) · Neoplasia · doi:10.1016/j.neo.2016.01.003 · Cited by 56
Dammeijer, F. F., Lievense, L. A., Veerman, G., Hoogsteden, H. C., Hegmans, J. P., Arends, L. R., & Aerts, J. G. J. V. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.3955 · Cited by 57
Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development
Liang, J., & Zhao, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0004 · Cited by 56
AACR Cancer Progress Report 2015
Baselga, J., Bhardwaj, N., Cantley, L. C., DeMatteo, R., DuBois, R. N., Foti, M., Gapstur, S. M., Hahn, W. C., Helman, L. J., Jensen, R. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1846 · Cited by 55
IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing
Pan, Y., Phillips, J. W., Zhang, B. D., Noguchi, M., Kutschera, E., McLaughlin, J., Nesterenko, P. A., Mao, Z., Bangayan, N. J., Wang, R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221116120 · Cited by 55
Cheng, H., Cui, Y., Wang, R., Kwon, N., & Yoon, J. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.04.004 · Cited by 55
Asadirad, A., Baghaei, K., Hashemi, S. M., Dehnavi, S., Ghanbarian, H., Mortaz, E., Anissian, A., Aghdaei, H. A., & Amani, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108493 · Cited by 55
Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities
Fu, C., Ma, T., Zhou, L., Mi, Q., & Jiang, A. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2109486 · Cited by 55
Therapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation
Kartikasari, A. E. R., Prakash, M. D., Cox, M., Wilson, K., Boer, J. C., Cauchi, J. A., & Plebanski, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03109 · Cited by 54
Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy
Ijsselsteijn, M. E., Pamplona, R. S., Hermitte, F., & de Miranda, N. F. C. C. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.003 · Cited by 54
The role of the immune system in brain metastasis.
Leibold, A. T., Monaco, G. N., & Dey, M. (2019) · PubMed · Cited by 54
Ramachandran, M., Dimberg, A., & Essand, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.010 · Cited by 54
Mechanisms of immunogenicity in colorectal cancer
Sillo, T. O., Beggs, A. D., Morton, D. G., & Middleton, G. (2019) · British journal of surgery · doi:10.1002/bjs.11204 · Cited by 53
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
Dillman, R. O. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1244149 · Cited by 53
Rawding, P. A., Bu, J., Wang, J., Kim, D., Drelich, A. J., Kim, Y. S., & Hong, S. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1752 · Cited by 52
Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy
Okada, M., Shimizu, K., & Fujii, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052594 · Cited by 52
Zanotta, S., Galati, D., Filippi, R. D., & Pinto, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147509 · Cited by 53
Predicting MHC-I ligands across alleles and species: how far can we go?
Tadros, D. M., Racle, J., & Gfeller, D. (2025) · Genome Medicine · doi:10.1186/s13073-025-01450-8 · Cited by 52
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 52
MASS SPECTROMETRY‐BASED PERSONALIZED DRUG THERAPY
Cui, J., Wang, L., Tan, Z., Zhou, H., Zhan, X., & Yin, J. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21620 · Cited by 52
Checkpoint immunotherapy in head and neck cancers
Zolkind, P., & Uppaluri, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9694-9 · Cited by 51
Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
Malissen, N., & Grob, J. (2018) · Drugs · doi:10.1007/s40265-018-0945-z · Cited by 51
Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers
Pao, S.-C., Chu, M.-T., & Chung, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040867 · Cited by 52
Spleen‐targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma
Wu, M., Luo, Z., Cai, Z., Mao, Q., Li, Z., Li, H., Zhang, C., Zhang, Y., Zhong, A., Wu, L., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216836 · Cited by 51
Challenges towards the realization of individualized cancer vaccines
Türeci, Ö., Löwer, M., Schrörs, B., Lang, M., Tadmor, A. D., & Şahin, U. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0266-2 · Cited by 51
An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines
Ott, P. A., Dotti, G., Yee, C., & Goff, S. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238001 · Cited by 51
Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications
Tang, L., Zhang, R., Zhang, X., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701777 · Cited by 51
Su, T., Liu, X., Lin, S., Cheng, F., & Zhu, G. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.02.016 · Cited by 50
Cancer vaccine: learning lessons from immune checkpoint inhibitors
Ye, Z., Qian, Q., Jin, H., & Qian, Q. (2017) · Journal of Cancer · doi:10.7150/jca.20059 · Cited by 50
Cai, W., Zhou, D., Wu, W., Tan, W. L., Wang, J., Zhou, C., & Lou, Y. (2018) · BMC Genomics · doi:10.1186/s12864-018-4958-5 · Cited by 50
Trained Immunity for Personalized Cancer Immunotherapy: Current Knowledge and Future Opportunities
Lérias, J. R., de Sousa, E., Paraschoudi, G., Martins, J. D., Condeço, C., Figueiredo, N., Carvalho, C. T., Dodoo, E., Maia, A., Castillo-Martín, M., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02924 · Cited by 50
Ichikawa, J., Yoshida, T., Isser, A., Laino, A. S., Vassallo, M., Woods, D. M., Kim, S., Oelke, M., Jones, K., Schneck, J. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3487 · Cited by 50
Tran, N. H., Qiao, R., Xin, L., Chen, X., Shan, B., & Li, M. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00260-4 · Cited by 50
Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
Salah, A., Wang, H., Li, Y., Ji, M., Ou, W., Qi, N., & Wu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.686544 · Cited by 50
Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition
Yuan, J. D., Khilnani, A. D., Brody, J., Andtbacka, R. H. I., Hu‐Lieskovan, S., Luke, J. J., Diab, A. K., Marabelle, A., Snyder, A., Cao, Z. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.004 · Cited by 50
Natural Polyphenols-Platinum Nanocomplexes Stimulate Immune System for Combination Cancer Therapy
Xiang, J., Zhang, Y., Liu, X., Zhou, Q., Piao, Y., Shao, S., Tang, J., Zhou, Z., Xie, T., & Shen, Y. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c02161 · Cited by 51
The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
Karpanen, T., & Olweus, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01718 · Cited by 49
Fomchenko, E. I., Bayley, J. C., Alvarez-Breckenridge, C. A., Rhines, L. D., & Tatsui, C. E. (2022) · Neurospine · doi:10.14245/ns.2244290.145 · Cited by 49
The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy
Cummings, C., Peters, E. J., Lacroix, L., André, F., & Lackner, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12429 · Cited by 49
Dendritic Cell Vaccines for Melanoma: Past, Present and Future
Dillman, R. O., Nistor, G. I., & Cornforth, A. N. (2016) · Melanoma Management · doi:10.2217/mmt-2016-0014 · Cited by 49
Jin, D., & Sprent, J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800031 · Cited by 49
Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside
Roy, S., Sethi, T. K., Taylor, D., Kim, Y. J., & Johnson, D. B. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5bt0420-585rr · Cited by 49
Targeting neoantigens for cancer immunotherapy: Table 1.
Lu, Y., & Robbins, P. F. (2016) · International Immunology · doi:10.1093/intimm/dxw026 · Cited by 48
Bräunlein, E., & Krackhardt, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01702 · Cited by 42
Peptide Delivery Systems for Cancer Vaccines
He, X., Abrams, S. I., & Lovell, J. F. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800060 · Cited by 48
Current Status of Immunotherapies for Treating Pancreatic Cancer
Wu, A. A., Jaffee, E. M., & Lee, V. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0811-5 · Cited by 48
Liao, J.-Y., & Zhang, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663264 · Cited by 48
Progress in Neoantigen Targeted Cancer Immunotherapies
Han, X.-J., Ma, X.-L., Yang, L., Wei, Y.-Q., Peng, Y., & Wei, X.-W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 47
Personalised neoantigen‐based therapy in colorectal cancer
Zhu, Y., Li, X., Chen, T., Wang, J., Zhou, Y., Mu, X., Du, Y., Wang, J., Tang, J., & Liu, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1461 · Cited by 47
Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy
Sheykhhasan, M., Ahmadieh-Yazdi, A., Heidari, R., Chamanara, M., Akbari, M., Poondla, N., Yang, P., Malih, S., Manoochehri, H., Tanzadehpanah, H., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117858 · Cited by 47
Current tools for predicting cancer-specific T cell immunity
Gfeller, D., Bassani‐Sternberg, M., Schmidt, J., & Luescher, I. F. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1177691 · Cited by 47
Immune therapy of melanoma: Overview of therapeutic vaccines
Payandeh, Z., Yarahmadi, M., Nariman‐Saleh‐Fam, Z., Tarhriz, V., Islami, M., Aghdam, A. M., & Eyvazi, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28181 · Cited by 47
Wu, Z., Wang, M.-R., Liu, Q., Liu, Y., Zhu, K., Chen, L., Guo, H., Li, Y., & Shi, B. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.39056 · Cited by 47
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 46
Updates in adjuvant systemic therapy for melanoma
Kwak, M., Farrow, N. E., Salama, A. K. S., Mosca, P. J., Hanks, B. A., Slingluff, C. L., & Beasley, G. M. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25298 · Cited by 46
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
Vormehr, M., Schrörs, B., Boegel, S., Löwer, M., Türeci, Ö., & Sahin, U. (2015) · Journal of Immunology Research · doi:10.1155/2015/595363 · Cited by 42
ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis
Sidhom, J.-W., Bessell, C. A., Havel, J. J., Kosmides, A., Chan, T. A., & Schneck, J. P. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0114 · Cited by 45
Targeting STING Activation by Antigen‐Inspired MnO2 Nanovaccines Optimizes Tumor Radiotherapy
Gu, Y., Lin, S., Wu, Y., Xu, P., Zhu, W., Wang, Y., Cheng, X., Zhang, L. W., Stauber, R. H., Wang, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300028 · Cited by 45
Lü, L., Weng, C., Mao, H., Fang, X., Liu, X., Wu, Y., Cao, X., Li, B., Chen, X., Gan, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7869 · Cited by 45
Zolkind, P., Przybylski, D., Marjanovic, N. D., Nguyễn, L., Lin, T., Johanns, T. M., Alexandrov, A., Zhou, L., Allen, C. T., Miceli, A. P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23751 · Cited by 45
Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth
Aurisicchio, L., Salvatori, E., Lione, L., Bandini, S., Pallocca, M., Maggio, R., Fanciulli, M., Nicola, F. D., Goeman, F., Ciliberto, G., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1084-4 · Cited by 45
Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives
Testori, A., Ribero, S., Indini, A., & Mandalà, M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00456-4 · Cited by 45
Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors
Mösch, A., Raffegerst, S. H., Weis, M., Schendel, D. J., & Frishman, D. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01141 · Cited by 45
Chen, R., Fulton, K. M., Twine, S. M., & Li, J. (2019) · Mass Spectrometry Reviews · doi:10.1002/mas.21616 · Cited by 47
Martin, S. D., Wick, D. A., Nielsen, J. S., Gierc, N. S., Holt, R. A., & Nelson, B. H. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1371895 · Cited by 45
(2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0422-y · Cited by 44
Mouse Models of Tumor Immunotherapy
Ngiow, S. F., Loi, S., Thomas, D. M., & Smyth, M. J. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.004 · Cited by 44
CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations
Nimanong, S., Ostroumov, D., Wingerath, J., Knocke, S., Woller, N., Gürlevik, E., Falk, C. S., Manns, M. P., Kühnel, F., & Wirth, T. C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2089 · Cited by 44
Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach
Kakwere, H., Ingham, E. S., Allen, R. P., Mahakian, L. M., Tam, S. M., Zhang, H., Silvestrini, M. T., Lewis, J. S., & Ferrara, K. W. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00502 · Cited by 44
Leclerc, M., Mezquita, L., Nerville, G. G. D., Tihy, I., Malenica, I., Chouaïb, S., & Mami‐Chouaib, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01505 · Cited by 44
Stolk, D. A., de Haas, A. M., Vree, J., Duinkerken, S., Lübbers, J., van de Ven, R., Ambrosini, M., Kalay, H., Bruijns, S. C. M., van der Vliet, H. J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00990 · Cited by 44
Dafni, U., Lluesma, S. M., Balint, K., Tsourti, Z., Vervita, K., Chenal, J., Coukos, G., Zaman, K., Sarivalasis, A., & Kandalaft, L. E. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.014 · Cited by 44
Liang, J., Cheng, K., Li, Y., Xu, J., Chen, Y., Ma, N., Feng, Q., Zhu, F., Ma, X., Zhang, T., et al. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.11.032 · Cited by 44
Neoantigens in precision cancer immunotherapy: from identification to clinical applications
Zhang, Q., Jia, Q., Zhang, J., & Zhu, B. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002181 · Cited by 44
Identifying neoantigens for use in immunotherapy
Hutchison, S., & Pritchard, A. L. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9771-6 · Cited by 43
Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas
Rathe, S. K., Popescu, F. E., Johnson, J. E., Watson, A. L., Marko, T. A., Moriarity, B. S., Ohlfest, J. R., & Largaespada, D. A. (2019) · Scientific Reports · doi:10.1038/s41598-018-36840-z · Cited by 43
Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity
Fennemann, F. L., de Vries, I. J. M., Figdor, C. G., & Verdoes, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00824 · Cited by 43
Wu, J., Chen, Z., Wickström, S. L., Gao, J., He, X., Xu, J., Wu, J., Du, Q., Yang, M., Chen, Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202101029 · Cited by 43
Bhatta, M., Shenoy, G. N., Loyall, J. L., Gray, B. D., Bapardekar, M. V., Conway, A. N., Minderman, H., Kelleher, R. J., Jr., Carreno, B. M., Linette, G. P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003148 · Cited by 43
Self-citationNeoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
Zheng, Y., Fu, Y., Wang, P., & Ding, Z. (2022) · Disease Markers · doi:10.1155/2022/8270305 · Cited by 43
Metadata
- Authors
- Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P.
- Affiliations
- Washington University in St. Louis (US)
- Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- University of Oklahoma Health Sciences Center (US)
- MilliporeSigma (United States) (US)
- Corresponding author
- Carreno, Beatriz M.
- ORCID
- Venue
- Science
- Published
- 2015-05-15
- Volume
- 348
- Issue
- 6236
- Pages
- 803-808
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4549796
- OpenAlex
- W2007026865
- Cited by
- 1,285
- References
- 37
- Citations by year
- 2026: 45 · 2025: 90 · 2024: 104 · 2023: 108 · 2022: 126 · 2021: 159 · 2020: 135 · 2019: 138 · 2018: 124 · 2017: 118 · 2016: 99 · 2015: 38
- FWCI
- 62.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (5U54HG00307)
- National Cancer Institute (P30 CA91842, R21 CA179695)
- Barnes-Jewish Hospital Foundation
- Siteman Cancer Frontier Fund
- Our Mark on Melanoma (MOM) Foundation
- Come Out Swinging (COS) Foundation
- Blackout Melanoma Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- dendritic cell vaccine, melanoma, neoantigens, missense mutations, T cell receptor repertoire, HLA-A*0201, T cell-mediated antitumor immunity, clonal diversity, cancer immunotherapy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Melanoma, Mutation, Skin Neoplasms, T-Lymphocytes, Monitoring, Immunologic, HLA-A2 Antigen, Immunotherapy, Active, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Cancer Vaccines, Amino Acid Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.